Search results
Results from the WOW.Com Content Network
The Global Appraisal of Individual Needs (GAIN) is a family of evidence-based instruments used to assist clinicians with diagnosis, placement, and treatment planning. The GAIN is used with both adolescents and adults in all kinds of treatment programs, including outpatient, intensive outpatient, partial hospitalization, methadone, short-term residential, long-term residential, therapeutic ...
The ASI-5 survey contains a total of 164 items inquiring about the general background of the patients (n= 28), their conditions in the respective areas would be asked in the following according to the participants' preference on privacy recorded during the development of ASI: 1) Medical health (n= 11) 2) Employment/ support status (n= 24) 3 & 4) Drug/ alcohol use (n= 35) 5) Illegal activity ...
It evaluates the cost-effectiveness of drugs in a similar way to the UK's NICE, [1] [3] and has come under some criticism from the drug industry. [2] ICER has placed a monetary value on several prescription drugs since 2014. Insurers have used those evaluations to justify which drugs are approved or denied.
Prescription drug monitoring programs, or PDMPs, are an example of one initiative proposed to alleviate effects of the opioid crisis. [1] The programs are designed to restrict prescription drug abuse by limiting a patient's ability to obtain similar prescriptions from multiple providers (i.e. “doctor shopping”) and reducing diversion of controlled substances.
Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.
It was reported in 2018 1.3 million drug addicts were treated in China's compulsory detox centers. [90] [91] Compulsory drug rehabilitation has a long history in China: The Mao Zedong government is credited with eradicating both consumption and production of opium during the 1950s using unrestrained repression and social reform.
FDA Building 51 is one of the main buildings in its White Oak campus that houses the Center for Drug Evaluation and Research. The Center for Drug Evaluation and Research (CDER, pronounced "see'-der") is a division of the U.S. Food and Drug Administration (FDA) that monitors most drugs as defined in the Food, Drug, and Cosmetic Act.
Using the program year estimates provided in the Contract as evidence of the bona fide need, NIDA must resolve these violations by deobligating $14.9 million ($20.2 million less $5.3 million) of fiscal year 2007 funds that were obligated in excess of the agency's bona fide need for program year 1 and obligating the appropriate fiscal year funds ...